To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

[Congressional Bills 117th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7640 Introduced in House (IH)]

<DOC>






117th CONGRESS
  2d Session
                                H. R. 7640

  To amend the Orphan Drug Act to reauthorize a program of grants and 
contracts for the development of drugs for rare diseases and conditions 
              (commonly referred to as ``orphan drugs'').


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 3, 2022

    Mr. Bilirakis (for himself and Mr. Butterfield) introduced the 
   following bill; which was referred to the Committee on Energy and 
                                Commerce

_______________________________________________________________________

                                 A BILL


 
  To amend the Orphan Drug Act to reauthorize a program of grants and 
contracts for the development of drugs for rare diseases and conditions 
              (commonly referred to as ``orphan drugs'').

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. REAUTHORIZATION OF GRANTS AND CONTRACTS FOR DEVELOPMENT OF 
              ORPHAN DRUGS.

    Section 5(c) of the Orphan Drug Act (21 U.S.C. 360ee(c)) is amended 
by striking ``2018 through 2022'' and inserting ``2023 through 2027''.
                                 <all>